Venmax Drugs & Pharmaceuticals
25.77
-0.13(-0.50%)
Market Cap₹22.80 Cr
PE Ratio26.16
IndustryHealthcare
Company Performance:
1D-0.50%
1M+1.50%
6M+16.40%
1Y-7.87%
5Y+291.64%
View Company Insightsright
More news about Venmax Drugs & Pharmaceuticals
21Jan 26
Venmax Drugs Allots 7.75 Lakh Equity Shares Through Warrant Conversion Worth ₹1.16 Crores
Venmax Drugs and Pharmaceuticals Limited allotted 7,75,000 equity shares on January 21, 2026, through warrant conversion by three non-promoter investors. The conversion was executed at ₹20 per share, generating ₹1,16,25,000 in proceeds and increasing the company's paid-up capital to ₹8,78,29,300. With 64,81,000 warrants still outstanding from the original March 2025 issuance, the company maintains potential for further capital expansion through future conversions.
 no imag found
24Nov 25
Venmax Drugs & Pharmaceuticals: Independent Director Dakshita Jain Steps Down
Mrs. Dakshita Jain, Non-Executive Independent Director of Venmax Drugs & Pharmaceuticals Limited, has resigned from the board effective November 24, 2025. The resignation, attributed to personal and professional commitments, was accepted by the board in a meeting on the same date. The company reported no other material reasons for her departure.
 no imag found
12Nov 25
Venmax Drugs Reports Strong Revenue Growth and Advances Amalgamation with Hatri Pharma
Venmax Drugs & Pharmaceuticals Limited (VDPL) reported a 669.7% increase in Q2 FY2026 revenue to Rs 131.85 lakhs and returned to profitability with Rs 2.44 lakhs net profit. Half-year revenue grew 818.9% to Rs 252.87 lakhs. The company is progressing with its proposed amalgamation with Hatri Pharma Private Limited, aiming for operational efficiencies and economies of scale. The amalgamation involves a 1:1 share exchange ratio. VDPL's total assets increased to Rs 1,364.68 lakhs, with improved equity and cash positions.
 no imag found
23Jul 25
Venmax Drugs & Pharmaceuticals Reports Rs 3.74 Lakh Profit in Q1 Results
Venmax Drugs & Pharmaceuticals Limited announced unaudited standalone financial results for Q1 ended June 30. The company reported revenue from operations of Rs 121.03 lakhs and achieved a profit of Rs 3.74 lakhs. Total expenses stood at Rs 117.29 lakhs. The balance sheet showed improvements with cash and cash equivalents increasing to Rs 251.94 lakhs and trade receivables rising to Rs 230.81 lakhs.
 no imag found
1 Year Returns:-7.87%
Industry Peers
Sun Pharmaceutical
1,757.20
(-2.03%)
Divis Laboratories
5,947.00
(-0.84%)
Torrent Pharmaceuticals
4,220.20
(-1.06%)
Dr Reddys Laboratories
1,254.90
(-2.09%)
Lupin
2,313.90
(-0.90%)
Cipla
1,224.20
(-1.46%)
Zydus Life Science
871.20
(-2.84%)
Mankind Pharma
2,005.80
(-1.62%)
Aurobindo Pharma
1,304.40
(-0.75%)
Alkem Laboratories
5,299.00
(-0.85%)